PE22-28 is a synthetic seven amino acid heptapeptide derived from positions 22 through 28 of the sortilin propeptide, where it is also referred to as minispadin. It is a shorter analog of spadin (PE12-28), the parent molecule released during maturation of sortilin, also known as NTSR3. This lesson covers its proposed mechanism, the preclinical evidence base, and the open questions that frame how it might be approached clinically.

One point deserves emphasis up front. The evidence for PE22-28 is preclinical, drawn from mouse and rat models and cell culture. There are no human phase one, two, or three trials, no human pharmacokinetics, no established dosing, and no FDA approval or IND filing that the speaker is aware of. The compound is classified as a research synthetic heptapeptide.

How it works

PE22-28 acts as a selective antagonist of TRK1, a background leak potassium channel in the K2P family that helps set a neuron’s resting membrane potential. When TRK1 leaks potassium, the cell hyperpolarizes and fires less. Blocking that leak shifts the membrane toward depolarization and increases neuronal excitability. In the dorsal raphe nucleus this is described as enhancing serotonergic firing without inhibiting the serotonin transporter, a mechanism distinct from SSRIs.

Downstream, the peptide is reported to engage the MAPK/ERK and PI3K/AKT cascades and a PKA-phosphorylated CREB to BDNF axis, with rapid BDNF upregulation in the hippocampus. In rodent models it triggers hippocampal neurogenesis within four days, compared with the roughly 21 days associated with SSRIs. It is described as 300 to 500 times more potent than spadin, with a duration of action up to 23 hours versus about 7 for spadin, and selectivity that spares TREK2, TRAAK, and TASK1.

Evidence and clinical context

The human-level signal comes from the STAR*D dataset, the largest antidepressant study conducted in the United States, which linked KCNK2 (TRK1) SNPs to differing antidepressant responses. As the speaker frames it, this validates TRK1 as a depression target in humans, but it does not validate PE22-28 as a human therapeutic.

The transcript notes anecdotal intranasal use as a possible bridge during the first weeks of SSRI therapy, with a referenced pattern of roughly 400 to 800 micrograms per nostril once daily. This is presented as evolving, unstandardized practice with no human data to validate it, and it is offered for understanding rather than as a protocol.

Key clinical points

• PE22-28 is a synthetic heptapeptide and selective TRK1 potassium channel antagonist, a shorter analog of spadin derived from the sortilin propeptide.
• Its proposed antidepressant action works through TRK1 blockade and serotonergic enhancement in the dorsal raphe, not serotonin transporter inhibition.
• Reported preclinical advantages include rapid four-day neurogenesis, BDNF and CREB pathway activation, high potency, and a long duration of action.
• All efficacy and safety data come from rodent or spadin studies. No human trials, pharmacokinetics, dosing standards, or long-term safety data exist.
• TRK1’s dual role in ischemic neuroprotection, cardiac tissue, and pain signaling raises theoretical concerns that warrant monitoring and further evaluation.